Rejoin your ADC combination speakers and attendees after lunch for a closing panel discussion to discuss, debate and evaluate the opportunities and challenges in combination clinical performance, optimising partner selection, the

power of ADC sequencing and dual payload conjugates, and more. Make sure to come with your thoughts and questions prepared!

Discussion Highlights Include:

• Explore the impact of ADC combination on the oncology treatment landscape: Will combination therapies become the norm as ADCs progress to earlier-line patient therapies?
• Understanding the best rationale to smartly select appropriate ADC combination partners
• Evaluating the ability of ADC sequencing and dual payload combinations to combat resistance to payloads